Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Deferred Taxes (2020 - 2025)

Bioventus (BVS) has disclosed Deferred Taxes for 6 consecutive years, with -$1.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Deferred Taxes fell 135.18% year-over-year to -$1.1 million, compared with a TTM value of -$909000.0 through Dec 2025, up 83.15%, and an annual FY2025 reading of -$909000.0, up 83.15% over the prior year.
  • Deferred Taxes was -$1.1 million for Q4 2025 at Bioventus, down from $135000.0 in the prior quarter.
  • Across five years, Deferred Taxes topped out at $3.2 million in Q4 2024 and bottomed at -$17.0 million in Q2 2022.
  • Average Deferred Taxes over 5 years is -$3.4 million, with a median of -$876000.0 recorded in 2023.
  • The sharpest move saw Deferred Taxes tumbled 20603.61% in 2022, then surged 176.44% in 2024.
  • Year by year, Deferred Taxes stood at -$8.1 million in 2021, then tumbled by 46.14% to -$11.8 million in 2022, then soared by 109.88% to $1.2 million in 2023, then surged by 176.44% to $3.2 million in 2024, then tumbled by 135.18% to -$1.1 million in 2025.
  • Business Quant data shows Deferred Taxes for BVS at -$1.1 million in Q4 2025, $135000.0 in Q3 2025, and $44000.0 in Q2 2025.